Rockwell Medical (RMTI) Stock Overview
Engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RMTI Community Fair Values
Create NarrativeSee what 13 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Rockwell Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.67 |
| 52 Week High | US$21.00 |
| 52 Week Low | US$4.89 |
| Beta | 1.61 |
| 1 Month Change | -9.25% |
| 3 Month Change | -38.83% |
| 1 Year Change | -48.92% |
| 3 Year Change | -86.47% |
| 5 Year Change | -93.06% |
| Change since IPO | -98.99% |
Recent News & Updates
Narrative Update • Jul 01
RMTI: Reverse Split And New Contracts Will Anchor Future Margin Discipline
Analysts have lifted their price target for Rockwell Medical to $40.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that they believe better reflect the company’s current outlook. What’s in the News for Rockwell Medical Rockwell Medical received written notice on May 8, 2026, that its stock is not in compliance with Nasdaq’s minimum bid price requirement of $1.00 per share, with an initial grace period through November 4, 2026, to regain compliance.
Narrative Update • Jun 16
RMTI: Dialysis Contract Wins Will Support Future Stock Price Repricing
Rockwell Medical's analyst price target has been revised lower, with recent updates citing adjusted assumptions on the discount rate, revenue growth, profit margin and future P/E to reflect a more cautious view from analysts at H.C. Wainwright and Maxim. Analyst Commentary Recent Street research on Rockwell Medical reflects a more cautious tone, with bearish analysts revisiting their models and trimming price targets to align with revised assumptions on discount rates, revenue expectations, profit margins and future P/E multiples.Analysis Article • Jun 06
At US$0.66, Is It Time To Put Rockwell Medical, Inc. (NASDAQ:RMTI) On Your Watch List?
Rockwell Medical, Inc. ( NASDAQ:RMTI ), might not be a large cap stock, but it saw significant share price movement...Narrative Update • Jun 02
RMTI: Dialysis Contract Momentum Will Drive Future Repricing Potential
Rockwell Medical's analyst price target has been revised downward by $1.50 in recent Street research, as analysts cite updated views on fair value, discount rates, revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research reflects a more cautious tone on Rockwell Medical, with bearish analysts trimming price targets as they revisit assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E levels.Narrative Update • May 17
RMTI: Dialysis Contract Wins Will Drive Future Repricing Potential
Rockwell Medical's analyst price target has shifted lower from $2.50 to $2.00, as analysts factor in updated assumptions around fair value, profitability, and a higher expected future P/E multiple, as reflected in recent research updates. Analyst Commentary Recent research updates on Rockwell Medical reflect a more cautious tone, with bearish analysts trimming price targets and reassessing the risk and reward tradeoff.Recent updates
Narrative Update • Jul 01
RMTI: Reverse Split And New Contracts Will Anchor Future Margin Discipline
Analysts have lifted their price target for Rockwell Medical to $40.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that they believe better reflect the company’s current outlook. What’s in the News for Rockwell Medical Rockwell Medical received written notice on May 8, 2026, that its stock is not in compliance with Nasdaq’s minimum bid price requirement of $1.00 per share, with an initial grace period through November 4, 2026, to regain compliance.Narrative Update • Jun 16
RMTI: Dialysis Contract Wins Will Support Future Stock Price Repricing
Rockwell Medical's analyst price target has been revised lower, with recent updates citing adjusted assumptions on the discount rate, revenue growth, profit margin and future P/E to reflect a more cautious view from analysts at H.C. Wainwright and Maxim. Analyst Commentary Recent Street research on Rockwell Medical reflects a more cautious tone, with bearish analysts revisiting their models and trimming price targets to align with revised assumptions on discount rates, revenue expectations, profit margins and future P/E multiples.Analysis Article • Jun 06
At US$0.66, Is It Time To Put Rockwell Medical, Inc. (NASDAQ:RMTI) On Your Watch List?
Rockwell Medical, Inc. ( NASDAQ:RMTI ), might not be a large cap stock, but it saw significant share price movement...Narrative Update • Jun 02
RMTI: Dialysis Contract Momentum Will Drive Future Repricing Potential
Rockwell Medical's analyst price target has been revised downward by $1.50 in recent Street research, as analysts cite updated views on fair value, discount rates, revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent Street research reflects a more cautious tone on Rockwell Medical, with bearish analysts trimming price targets as they revisit assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E levels.Narrative Update • May 17
RMTI: Dialysis Contract Wins Will Drive Future Repricing Potential
Rockwell Medical's analyst price target has shifted lower from $2.50 to $2.00, as analysts factor in updated assumptions around fair value, profitability, and a higher expected future P/E multiple, as reflected in recent research updates. Analyst Commentary Recent research updates on Rockwell Medical reflect a more cautious tone, with bearish analysts trimming price targets and reassessing the risk and reward tradeoff.
Narrative Update • Apr 28
RMTI: Reset Price Views Will Highlight Rebound In Growth Expectations
Analysts have reduced their Rockwell Medical price targets by $0.50 to $1.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margins and future P/E, which together indicate a lower valuation anchor for the stock. Analyst Commentary Bullish Takeaways Bullish analysts appear to see the revised targets as a recalibration to updated fair value assumptions rather than a fundamental shift in the long term story.Narrative Update • Apr 13
RMTI: Future Earnings Framework Will Center On Execution And Margin Discipline
For Rockwell Medical, the analyst price target has been reduced by $0.50 to $1 and by $1 to $1.50, with analysts pointing to updated assumptions on fair value, discount rate, revenue growth, profit margins, and future P/E multiples to support the shift. Analyst Commentary Bullish analysts, even while trimming their price targets, are still framing Rockwell Medical's valuation around updated assumptions that keep upside scenarios on the table.Narrative Update • Mar 30
RMTI: Extended Dialysis Contracts Will Support Future Repricing Potential
Analysts have trimmed their price target on Rockwell Medical by $1 to reflect updated views on discount rates, revenue growth, profit margins, and expected future P/E levels. Analyst Commentary Bearish analysts have trimmed the price target on Rockwell Medical by $1, which signals a more cautious stance on how the company might justify its valuation relative to its fundamentals.Narrative Update • Mar 12
RMTI: Extended Dialysis Contracts Will Support Future Repricing Potential
Analysts have modestly adjusted their price target for Rockwell Medical to $2.50, citing small recalibrations to the discount rate, revenue growth assumptions, profit margin outlook, and forward P/E expectations. What's in the News Rockwell Medical issued preliminary unaudited guidance for the fourth quarter of 2025, with expected net sales of approximately US$18.6 million for the period.Narrative Update • Feb 25
RMTI: Extended Dialysis Contracts And New Customers Will Support Future Repricing
Analysts have trimmed their price targets on Rockwell Medical to reflect updated assumptions that keep fair value steady at $2.50, while modestly adjusting the discount rate, revenue growth, profit margin, and future P/E inputs in their models. What's in the News Issued preliminary unaudited guidance for fourth quarter 2025 net sales of approximately US$18.6 million.Narrative Update • Feb 11
RMTI: Diversified Revenue And Extended Contracts Will Support Future Repricing
Analysts have lowered their Rockwell Medical price target to $2.50 from $3.00, citing slightly weaker Q3 revenue and updated long-term assumptions that indicate a more diversified but less contract-driven revenue mix, along with a modestly lower future P/E outlook. Analyst Commentary Bearish analysts are framing the lower US$2.50 price target as a reset that better aligns Rockwell Medical's valuation with a more modest growth profile and less reliance on large, high visibility contracts.Analysis Article • Feb 03
Rockwell Medical, Inc.'s (NASDAQ:RMTI) Shares Bounce 32% But Its Business Still Trails The Industry
Rockwell Medical, Inc. ( NASDAQ:RMTI ) shares have had a really impressive month, gaining 32% after a shaky period...Narrative Update • Jan 27
RMTI: Diversified Revenue And Extended Contracts Will Support Future Upside
Narrative Update Analysts have trimmed their price target on Rockwell Medical to US$2.50 from US$3.00, reflecting adjusted long term forecasts after a slight Q3 top line miss and expectations that the now more diversified revenue base may not benefit from large contracts to the same extent as before. Analyst Commentary Bearish analysts are signaling a more cautious stance on Rockwell Medical after the recent Q3 top line miss and the cut in the price target to US$2.50 from US$3.Narrative Update • Jan 10
RMTI: Diversified Revenue Base And Contract Extension Will Support Future Upside
Analysts have trimmed their price target on Rockwell Medical to US$2.50 from US$3.00, citing slightly weaker recent revenue results and an updated view that the now more diversified revenue base may not see the same benefit from large contracts as it did previously. Analyst Commentary Bearish analysts have reacted to Rockwell Medical's recent results by trimming their expectations, pointing to a mix of softer revenue and recalibrated growth assumptions.Analysis Article • Dec 17
Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Narrative Update • Dec 15
RMTI Will Seek Upside As Diversified Revenue Base Supports Future Stability
Analysts have trimmed their price target on Rockwell Medical to $2.50 from $3.00. This reflects slightly more conservative long-term revenue assumptions after recent results showed a modest top-line miss and a more diversified but less contract-driven revenue base.Analysis Article • Oct 12
Why Investors Shouldn't Be Surprised By Rockwell Medical, Inc.'s (NASDAQ:RMTI) 32% Share Price Plunge
Rockwell Medical, Inc. ( NASDAQ:RMTI ) shares have had a horrible month, losing 32% after a relatively good period...Analysis Article • Aug 28
There's No Escaping Rockwell Medical, Inc.'s (NASDAQ:RMTI) Muted Revenues Despite A 43% Share Price Rise
Despite an already strong run, Rockwell Medical, Inc. ( NASDAQ:RMTI ) shares have been powering on, with a gain of 43...Analysis Article • Aug 19
Rockwell Medical, Inc. (NASDAQ:RMTI) Shares Could Be 34% Below Their Intrinsic Value Estimate
NasdaqCM:RMTI 1 Year Share Price vs Fair Value Explore Rockwell Medical's Fair Values from the Community and select...Analysis Article • Jul 11
Rockwell Medical, Inc. (NASDAQ:RMTI) Held Back By Insufficient Growth Even After Shares Climb 25%
Rockwell Medical, Inc. ( NASDAQ:RMTI ) shareholders have had their patience rewarded with a 25% share price jump in the...Analysis Article • Jun 26
We Think Rockwell Medical (NASDAQ:RMTI) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Narrative • Apr 10
Acquisition Of Evoqua And Global Moves Will Face Revenue Challenges
Strategic diversification and global expansion efforts aim to capture new markets and improve revenue, counteracting dependency on major existing customers.Analysis Article • Mar 21
Rockwell Medical, Inc.'s (NASDAQ:RMTI) 26% Dip In Price Shows Sentiment Is Matching Revenues
To the annoyance of some shareholders, Rockwell Medical, Inc. ( NASDAQ:RMTI ) shares are down a considerable 26% in the...Analysis Article • Mar 19
Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jan 06
Rockwell Medical (NASDAQ:RMTI) Might Have The Makings Of A Multi-Bagger
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Typically, we'll want to...Analysis Article • Nov 15
Rockwell Medical, Inc.'s (NASDAQ:RMTI) 28% Dip In Price Shows Sentiment Is Matching Revenues
Rockwell Medical, Inc. ( NASDAQ:RMTI ) shareholders won't be pleased to see that the share price has had a very rough...Analysis Article • Nov 14
Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Trimmed Their Revenue Forecasts By 15%
Today is shaping up negative for Rockwell Medical, Inc. ( NASDAQ:RMTI ) shareholders, with the analysts delivering a...Analysis Article • Sep 29
The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More
Rockwell Medical, Inc. ( NASDAQ:RMTI ) shares have continued their recent momentum with a 28% gain in the last month...Seeking Alpha • Sep 15
Rockwell Medical: The Turnaround Is Looking Real
Summary Rockwell develop concentrates for hemodialysis, which is a process that seeks to artificially replace kidney function in patients with chronic failure. Despite being a critical product, there's currently no large competitor dominating the category and the company is a leader. After years of constant CEO turnover and poor results, Mr. Mark Strobeck has turned around and has already reached its first profitable quarter ever. The expectation is to reach a gross margin of 25% in 2025, but if it were reached in 2028, the shares could more than double according to my estimates. Read the full article on Seeking AlphaAnalysis Article • Aug 11
Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Shareholders will be ecstatic, with their stake up 23% over the past week following Rockwell Medical, Inc. 's...Analysis Article • Jul 12
Rockwell Medical, Inc.'s (NASDAQ:RMTI) Subdued P/S Might Signal An Opportunity
Rockwell Medical, Inc.'s ( NASDAQ:RMTI ) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy...Analysis Article • May 08
Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Shareholder Returns
| RMTI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.3% | -1.7% | -0.9% |
| 1Y | -48.9% | -18.9% | 19.4% |
Return vs Industry: RMTI underperformed the US Medical Equipment industry which returned -18.8% over the past year.
Return vs Market: RMTI underperformed the US Market which returned 20.3% over the past year.
Price Volatility
| RMTI volatility | |
|---|---|
| RMTI Average Weekly Movement | 8.4% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RMTI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: RMTI's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 157 | Mark Strobeck | www.rockwellmed.com |
Rockwell Medical, Inc., together with its subsidiaries, engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. It offers citrapure citric acid concentrate, dri-sate dry acid concentrate, renalpure liquid acid concentrate, dri-sate acid concentrate mixer, renalpure acid concentrate, renalpure bicarbonate concentrate, sterilyte bicarbonate concentrate, bicarbonate cartridges, and dry acid concentrate mixer, as well as ancillary products, including 5% acetic acid, cleaner, citric acid descaler, water softener salt pellets, and other supplies used by hemodialysis providers. The company’s hemodialysis concentrate products are used to sustain patient’s life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream.
Rockwell Medical, Inc. Fundamentals Summary
| RMTI fundamental statistics | |
|---|---|
| Market cap | US$22.14m |
| Earnings (TTM) | -US$5.56m |
| Revenue (TTM) | US$67.68m |
0.3x
P/S Ratio-4.0x
P/E RatioIs RMTI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RMTI income statement (TTM) | |
|---|---|
| Revenue | US$67.68m |
| Cost of Revenue | US$56.13m |
| Gross Profit | US$11.55m |
| Other Expenses | US$17.11m |
| Earnings | -US$5.56m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.41 |
| Gross Margin | 17.07% |
| Net Profit Margin | -8.21% |
| Debt/Equity Ratio | 25.0% |
How did RMTI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/13 10:05 |
| End of Day Share Price | 2026/07/13 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rockwell Medical, Inc. is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Ritu Baral | Canaccord Genuity |
| Ling Wang | Chardan Capital Markets, LLC |